| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CPT.1818 |
| P698 | PubMed publication ID | 32119114 |
| P50 | author | Sanjay K Nigam | Q111165276 |
| P2093 | author name string | Kevin T Bush | |
| Samuel M Poloyac | |||
| Jeremiah D Momper | |||
| Vibha Bhatnagar | |||
| P2860 | cites work | Secondary bile acids: an underrecognized cause of colon cancer | Q21245602 |
| A comprehensive review on metabolic syndrome | Q21284500 | ||
| OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia | Q24297458 | ||
| Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health | Q24618018 | ||
| Genome-wide association analyses identify 18 new loci associated with serum urate concentrations | Q24620065 | ||
| Bile acid transporters in health and disease | Q24647024 | ||
| Bile acid transporters | Q24652624 | ||
| Arachidonic acid cytochrome P450 epoxygenase pathway | Q24653023 | ||
| Bile acids: regulation of synthesis | Q24658139 | ||
| Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature | Q26769661 | ||
| Bile acid metabolism and signaling | Q27002873 | ||
| SLC transporters as therapeutic targets: emerging opportunities | Q27014726 | ||
| Bile acid transporters: structure, function, regulation and pathophysiological implications | Q28027885 | ||
| The organic anion transporter (OAT) family: a systems biology perspective | Q28085671 | ||
| Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases | Q28183769 | ||
| Intestinal bile acid transport: biology, physiology, and pathophysiology | Q28200862 | ||
| Clinical importance of the cytochromes P450 | Q28208454 | ||
| The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp | Q43662706 | ||
| High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases | Q43726094 | ||
| Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump | Q43899918 | ||
| Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics | Q46076879 | ||
| Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease | Q46373710 | ||
| Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System | Q47135121 | ||
| The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease. | Q47198594 | ||
| Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape | Q47724152 | ||
| Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence | Q47813133 | ||
| Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins | Q47895958 | ||
| Role of the blood-cerebrospinal fluid barrier transporter as a cerebral clearance system for prostaglandin E₂ produced in the brain. | Q48376982 | ||
| High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. | Q48910620 | ||
| Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway. | Q49258083 | ||
| Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. | Q51819821 | ||
| Inhibition of cytochromes P450 by nitric oxide and a nitric oxide-releasing agent. | Q52404730 | ||
| Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. | Q52541251 | ||
| Role of cGMP versus 20-HETE in the vasodilator response to nitric oxide in rat cerebral arteries | Q57219771 | ||
| Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries | Q57220836 | ||
| Low frequency of CYP2D6 poor metabolizers among schizophrenia patients | Q57585840 | ||
| Debrisoquine hydroxylation polymorphism and personality | Q69367946 | ||
| Microsomal cytochrome P450 and eicosanoid metabolism | Q74377754 | ||
| Systems Biology Analysis Reveals Eight SLC22 Transporter Subgroups, Including OATs, OCTs, and OCTNs | Q90162435 | ||
| Neuroprotective effects of epoxyeicosatrienoic acids | Q90381233 | ||
| Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling | Q91387197 | ||
| Remote sensing and signaling in kidney proximal tubules stimulates gut microbiome-derived organic anion secretion | Q92153121 | ||
| Unique metabolite preferences of the drug transporters OAT1 and OAT3 analyzed by machine learning | Q92379390 | ||
| Development of a new Japanese guideline on drug interaction for drug development and appropriate provision of information | Q92420479 | ||
| Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices | Q92505600 | ||
| A Network of SLC and ABC Transporter and DME Genes Involved in Remote Sensing and Signaling in the Gut-Liver-Kidney Axis | Q92647570 | ||
| Quantitative Systems Pharmacology: A Regulatory Perspective on Translation | Q92695741 | ||
| Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approach | Q95795711 | ||
| An Organic Anion Transporter 1 (OAT1)-centered Metabolic Network | Q39579026 | ||
| Pharmacological treatment of gallstones. Practical guidelines | Q40389377 | ||
| Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. | Q40449494 | ||
| Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. | Q40468022 | ||
| Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases | Q40539522 | ||
| Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). | Q40637524 | ||
| Evolution of gene expression patterns in a model of branching morphogenesis | Q40923783 | ||
| Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members | Q41905911 | ||
| Prostaglandin E2 produced by microsomal prostaglandin E synthase-1 regulates the onset and the maintenance of wakefulness | Q42491994 | ||
| Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine | Q42872165 | ||
| Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. | Q43244977 | ||
| Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump | Q43541919 | ||
| Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine | Q28242281 | ||
| Bile acid signaling in metabolic disease and drug therapy | Q28244875 | ||
| Cytochrome P450 eicosanoids in hypertension and renal disease | Q28252210 | ||
| Cytochrome P450 eicosanoids and cerebral vascular function | Q28396302 | ||
| Developmentally regulated expression of organic ion transporters NKT (OAT1), OCT1, NLT (OAT2), and Roct | Q28508498 | ||
| Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2 | Q28575931 | ||
| Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney | Q28592258 | ||
| A novel transporter of SLC22 family specifically transports prostaglandins and co-localizes with 15-hydroxyprostaglandin dehydrogenase in renal proximal tubules | Q28593864 | ||
| Identification of a novel murine organic anion transporter family member, OAT6, expressed in olfactory mucosa | Q28594438 | ||
| Cytochrome P450 metabolites of arachidonic acid in the control of renal function | Q31980650 | ||
| Kidney-specific expression of a novel mouse organic cation transporter-like protein | Q32166516 | ||
| Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia | Q33237883 | ||
| Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion | Q33395633 | ||
| ABC transporters in cellular lipid trafficking | Q34069104 | ||
| Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. | Q34119825 | ||
| Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). | Q34176588 | ||
| Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance | Q34241858 | ||
| Evidence that brain prostaglandin E2 is involved in physiological sleep-wake regulation in rats | Q34293292 | ||
| The organic anion transporter family: from physiology to ontogeny and the clinic | Q34310328 | ||
| Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer | Q34425909 | ||
| Bile acids and the gut microbiome | Q34432618 | ||
| Multiple organic anion transporters contribute to net renal excretion of uric acid | Q34470733 | ||
| Overview: ABC transporters and human disease | Q34502433 | ||
| Functional interactions between P-glycoprotein and CYP3A in drug metabolism | Q34550483 | ||
| Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation | Q34606100 | ||
| Cytochrome P450 pathways of arachidonic acid metabolism. | Q34667725 | ||
| Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis | Q34865706 | ||
| Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update | Q34871636 | ||
| Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. | Q35015581 | ||
| Dual role of cAMP in the transcriptional regulation of multidrug resistance-associated protein 4 (MRP4) in pancreatic adenocarcinoma cell lines | Q35195574 | ||
| An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters | Q35206374 | ||
| Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). | Q35446350 | ||
| Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. | Q35763029 | ||
| Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. | Q35775875 | ||
| Multispecific Organic Cation Transporter 1 (OCT1) from Bos taurus Has High Affinity and Slow Binding Kinetics towards Prostaglandin E2. | Q35979992 | ||
| Induction of phase I, II and III drug metabolism/transport by xenobiotics | Q36099291 | ||
| Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. | Q36226671 | ||
| Uremic Solutes in Chronic Kidney Disease and Their Role in Progression | Q36235662 | ||
| 20-HETE is associated with unfavorable outcomes in subarachnoid hemorrhage patients | Q36267499 | ||
| Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling | Q36294227 | ||
| Shared Ligands Between Organic Anion Transporters (OAT1 and OAT6) and Odorant Receptors | Q36316477 | ||
| Human cytochromes P450 in health and disease | Q36512912 | ||
| What do drug transporters really do? | Q36571217 | ||
| The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis | Q36664974 | ||
| Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation | Q36734132 | ||
| cDNA cloning of three new forms of rat brain cytochrome P450 belonging to the CYP4F subfamily | Q36790347 | ||
| Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling | Q36951216 | ||
| Growth hormone treatment of premature ovarian failure in a mouse model via stimulation of the Notch-1 signaling pathway | Q37001887 | ||
| Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics | Q37167278 | ||
| Multispecific drug transporter Slc22a8 (Oat3) regulates multiple metabolic and signaling pathways | Q37193094 | ||
| Targeting bile-acid signalling for metabolic diseases | Q37231731 | ||
| Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis | Q37314370 | ||
| Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke. | Q37440238 | ||
| Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. | Q37611786 | ||
| CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials | Q37678050 | ||
| In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy | Q37811961 | ||
| Pharmacological mechanism-based drug safety assessment and prediction | Q37864922 | ||
| Bile acid transporters and regulatory nuclear receptors in the liver and beyond | Q38033967 | ||
| Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective | Q38078188 | ||
| Role of ABC transporters in lipid transport and human disease | Q38082105 | ||
| Physiological and molecular biochemical mechanisms of bile formation | Q38164702 | ||
| Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. | Q38300264 | ||
| Future Avenues to Decrease Uremic Toxin Concentration | Q38616213 | ||
| The drug transporter OAT3 (SLC22A8) regulates endogenous metabolite flow through the gut-liver-kidney axis | Q38648038 | ||
| Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes | Q38685365 | ||
| Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions | Q38729347 | ||
| Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism | Q38869873 | ||
| Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology | Q39431317 | ||
| P577 | publication date | 2020-03-02 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | The Systems Biology of Drug Metabolizing Enzymes and Transporters: Relevance to Quantitative Systems Pharmacology |
| Q100564981 | The Role of the Microbiome in Central Nervous System Clinical Pharmacology: More Than a Gut Feeling | cites work | P2860 |
Search more.